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Undernutrition in children is a pressing global health problem,
manifested in part by impaired linear growth (stunting). Current
nutritional interventions have been largely ineffective in over-
coming stunting, emphasizing the need to obtain better under-
standing of its underlying causes. Treating Bangladeshi children
with severe acute malnutrition with therapeutic foods reduced
plasma levels of a biomarker of osteoclastic activity without
affecting biomarkers of osteoblastic activity or improving their
severe stunting. To characterize interactions among the gut
microbiota, human milk oligosaccharides (HMOs), and osteoclast
and osteoblast biology, young germ-free mice were colonized
with cultured bacterial strains from a 6-mo-old stunted infant and
fed a diet mimicking that consumed by the donor population.
Adding purified bovine sialylated milk oligosaccharides (S-BMO)
with structures similar to those in human milk to this diet
increased femoral trabecular bone volume and cortical thickness,
reduced osteoclasts and their bone marrow progenitors, and
altered regulators of osteoclastogenesis and mediators of
Th2 responses. Comparisons of germ-free and colonized mice
revealed S-BMO-dependent and microbiota-dependent increases in
cecal levels of succinate, increased numbers of small intestinal tuft
cells, and evidence for activation of a succinate-induced tuft cell
signaling pathway linked to Th2 immune responses. A prominent
fucosylated HMO, 2′-fucosyllactose, failed to elicit these changes
in bone biology, highlighting the structural specificity of the S-
BMO effects. These results underscore the need to further char-
acterize the balance between, and determinants of, osteoclastic
and osteoblastic activity in stunted infants/children, and suggest
that certain milk oligosaccharides may have therapeutic utility in
this setting.
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Undernutrition is a pressing global health challenge, annuallycontributing to the deaths of more than 3 million children
younger than 5 y (1). Infants and children whose length-for-age
z-score (LAZ) is at least two SDs below the median of the World
Health Organization’s Child Growth Standard (LAZ <−2) are
defined as stunted. Efforts to reduce stunting through nutritional
interventions have been largely ineffective (2). Moreover, the
long-term sequelae of stunting, including poor vaccine responses,
complications in pregnancy, reduced cognitive ability, and loss of
economic productivity, contribute to the intergenerational cycle
of undernutrition (3, 4). Numerous factors, ranging from micro-
nutrient deficiencies to enteropathogen exposure, systemic inflam-
mation, and host genetic/epigenetic features, have been invoked to
explain stunting in undernourished children (5–7). However, a more
comprehensive molecular characterization of the biological state of
children with undernutrition is needed to ascertain the mechanisms
underlying linear growth faltering, to understand why current treat-
ments fail, and to develop new interventions with significantly greater
efficacy.
In the present report, we examine interactions among milk oli-
gosaccharides, osteoclast and osteoblast biology, and components of
the immune system to gain insights about the pathogenesis of
stunting. Our rationale for examining these interactions are as fol-
lows. First, there is little information about how stunting correlates
with the number and activity of myeloid-derived osteoclasts that
degrade bone surface and osteoblasts that produce new bone.
Second, the immune system plays a major role in the differentiation
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of both the osteoclast and osteoblast lineages and in regulating
their function (8–10). Insulin-like growth factor-1 (IGF1) is a key
effector in the growth hormone signaling pathway that influences
bone growth and other facets of postnatal development. Proin-
flammatory cytokines, such as IL-6, TNFα, and IL-1β, can reduce
growth hormone (GH) receptor levels in liver and in the growth
plates of bones; they also impair GH signaling via suppressor of
cytokine signaling (SOCS)-mediated inhibition of JAK2 and
STAT activity (11), leading to impaired responsiveness to IGF1. In
addition to their effects on IGF1 activity, proinflammatory cyto-
kines can affect bone production through effects on PI3K/
Akt2 and JAK/STAT3 signaling pathways that control survival and
differentiation of osteoblasts (12). A similar relationship between
systemic inflammation and impaired GH/IGF1 signaling has been
implicated in the linear growth deficiency that develops in children
with inflammatory bowel disease (13–15) and chronic renal failure
(16). Third, human milk oligosaccharides (HMOs) are branched
or linear structures composed of glucose, galactose, and N-
acetylglucosamine residues that can be decorated with fucose or
sialic acid in a number of linkage configurations. A study of two
Malawian birth cohorts disclosed that sialylated milk oligosac-
charides were significantly less abundant in mothers with severely
stunted infants (17). Preclinical evidence of a connection between
HMOs and bone growth was provided by studies of young gno-
tobiotic mice colonized with a consortium of bacterial strains
cultured from the fecal microbiota of a 6-mo-old stunted Mala-
wian infant (17). Mice were fed a prototypic Malawian diet with or
without sialylated milk oligosaccharide structures purified from
bovine milk (S-BMO) that are also present in human breast milk.
Microcomputed tomography of their femurs disclosed that S-BMO
supplementation was associated with significant increases in the
volume of trabecular bone, as well as cortical bone (17).
In the current study, we show that a cohort of stunted children
with severe acute malnutrition (SAM) exhibit increased osteo-
clastic activity before therapeutic food intervention, without
effects on osteoblastic activity. We use gnotobiotic mice to
demonstrate how S-BMO produces effects on bone growth
through selective reductions in osteoclastogenesis, while sparing
osteoblast activity. These effects are not evident in colonized
mice treated with 2′-fucosyllactose (2′-FL), a representative of
the structurally diverse and prominent fucosylated oligosaccha-
rides present in breast milk. Our results identify interactions
between milk oligosaccharides and the gut microbiota that pro-
vide potential new therapeutic targets for overcoming the here-
tofore intractable problem of stunting in undernourished
children.
Results
Assessing Osteoclastic and Osteoblastic Activity in Children with
Severe Acute Malnutrition. A cohort of Bangladeshi children
with SAM (weight-for-height Z-score < −3) were enrolled in a
randomized, double-blind study to compare the efficacy of two
locally produced, ready-to-use therapeutic foods and a com-
mercially available ready-to-use therapeutic food on the rate of
weight gain after subjects had first been stabilized, using a
hospital-based, standardized management protocol for SAM
(18). After initial stabilization, children were randomly assigned
into one of the three treatment groups and provided ∼200 kcal of
the ready-to-use therapeutic food/kg/d until they had achieved
an edema-free weight-for-height Z-score of at least −2, at which
time they were discharged from the hospital. A subcohort of
54 children aged 17 ± 7.5 (mean ± SD) mo at enrollment was
followed at regular intervals up to 12 mo after discharge, with
blood samples obtained at enrollment, after completing treatment
(mean duration, 16 d) and 6 mo postdischarge. Linear growth was
assessed by anthropometry monthly for 6 mo. Despite their positive
effects on short-term weight gain, none of the interventions resulted
in a significant improvement in their severe stunting [LAZ; −3.32 ±
1.47 (mean ± SD) at enrollment, −3.31 ± 1.32 after 6 mo post-
discharge; P = 0.97, Wilcoxon matched-pairs signed rank test].
We used plasma samples serially collected from these children
before and after treatment to measure biomarkers and regula-
tors of bone turnover. The results revealed that C-Terminal
Telopeptide of Type I Collagen (CTX-I), a biomarker released
during osteoclastic bone degradation (19), decreased signifi-
cantly after nutritional therapy (Fig. 1A). IL-6 and TNFα, both
known pro-osteoclastogenic cytokines (20, 21), also decreased
significantly 6 mo after therapy, as did C-reactive protein (CRP),
an acute-phase reactant that can increase osteoclast numbers
(Fig. 1 B–D). In contrast, Pro-Collagen Type I Propeptide
(P1NP), a marker of osteoblastic bone production, did not
change (Fig. 1E). We concluded that although the nutritional
interventions did not significantly change LAZ scores, they al-
tered levels of CTX-I and inflammatory mediators in ways that
would be anticipated to reduce osteoclast number/activity.
S-BMO Diminishes Bone Resorption in Gnotobiotic Mice Colonized
with Gut Bacteria from a Stunted 6-Mo-Old Infant. On the basis of
these findings, we turned to the gnotobiotic mouse model de-
scribed in the Introduction to examine whether S-BMO affects
the balance between osteoclast and osteoblast number and ac-
tivity. Dietary information obtained from Malawian infants
during the period of complementary feeding was used to generate
a representative diet consisting of eight principal ingredients
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Fig. 1. Characterization of bone and immune biomarkers in Bangladeshi children with SAM before and after nutritional intervention. Plasma samples were
obtained before treatment, immediately after treatment, and at 6 mo follow-up (n = 40–49 samples/analyte). Mean values ± SEM are plotted for CTX-I (A), IL-
6 (B), TNFα (C), CRP (D), and P1NP (E). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 (repeated measures ANOVA followed by Tukey’s adjusted com-
parisons of group means; IL-6 and CRP were log10 transformed to meet the distributional assumptions of the test).
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[M8 (17)]. S-BMO was obtained from de-lactosed permeate, a
dairy ingredient developed as a coproduct of whey protein isola-
tion; deproteinization and removal of lactose was achieved by
ultrafiltration and diafiltration (22). Mass spectrometry of the
resulting oligosaccharide-enriched fraction established that it was
composed primarily of 3′-sialyllactose and 6′-sialyllactose (88% of
the oligosaccharide content), with the remaining structures con-
sisting of neutral trihexoses of glucose, galactose, and N-acetyl-
glucosamine-galactosamine and longer neutral oligosaccharides
(see ref. 17). Given that sialyllactose is present in human milk,
sialyllactose is the predominant oligosaccharide among the
15 structures identified in the S-BMO preparation, and S-BMO
was obtained from a scalable source, this preparation provided an
attractive starting point for our study.
S-BMO was added to the M8 diet at a level that approximated
HMO levels in breastmilk (17). Five-week-old male germ-free
C57BL6/J mice (n = 10 animals/treatment group in an initial
experiment; n = 5/group in a repeat experiment; Fig. 2A) were
monotonously fed either the unsupplemented M8 diet or
M8 supplemented with S-BMO (both diets have comparable
caloric density; 1.65 vs. 1.67 kcal/g, as defined by bomb calo-
rimetry; ref. 17). The diets were begun 3 d before gavage with a
defined consortium of bacterial strains cultured from a severely
stunted 6-mo-old infant (LAZ, −3.48; ref. 17 and Dataset S1A).
16S rDNA sequence-based analysis of the infant’s fecal micro-
biota had previously revealed that 78% of its bacterial compo-
sition (summed relative abundance of 97% identity Operational
Taxonomic Units) was captured in this culture collection (17).
Community profiling by shotgun sequencing [COPRO-Seq
(23)] of DNA prepared from cecal contents harvested from mice
at the time of euthanasia 39 d postgavage (dpg), disclosed that
consumption of S-BMO had no statistically significant effects on
the representation of all but one low abundance member of the
defined consortium (Dataset S1A). S-BMO supplementation
resulted in significantly greater increases in total body weight,
consistent with our earlier results (17). Quantitative magnetic
resonance measurements performed on dpg 4 and dpg 38 dis-
closed that S-BMO administration produced significantly greater
increases in lean body mass, and to a lesser extent fat mass,
compared with control animals fed unsupplemented M8 (Fig. 2
B–D). Microcomputed tomography of femurs documented that
S-BMO treatment produced statistically significant increases in
trabecular bone volume (defined by bone volume normalized to
tissue volume) and increased trabecular number (Fig. 2 E and F).
Cortical bone thickness was also augmented, although this dif-
ference did not achieve statistical significance (P = 0.06, Mann–
Whitney U test; Fig. 2G).
Analysis of serum samples obtained at the time of euthanasia
revealed that consumption of the S-BMO-supplemented M8 diet
produced a statistically significant reduction in circulating levels
of CTX-I compared with the unsupplemented diet, but no sig-
nificant differences in either serum P1NP or IGF1 (Fig. 2 H–J
and Dataset S2). Staining tibial sections for tartrate-resistant
alkaline phosphatase demonstrated a significant reduction in
the number of osteoclasts per bone surface area, as well as re-
ductions in total osteoclast number in S-BMO-treated mice (Fig.
2 K–M). Dynamic histomorphometry was performed by admin-
istering two dyes that are incorporated into growing bone (24):
the first, calcein green, was given by i.p. injection 9 d before
euthanasia; the second, alizarin red, was administered intraper-
itoneally 7 d later. The results revealed no significant effect of S-
BMO on the rate of tibial bone formation per bone surface area,
or on mineral apposition rate (Fig. 2 N–P). Serum levels of
granulocyte-colony stimulating factor, which can induce apo-
ptosis of mature osteoblasts, were not significantly different be-
tween the two treatment groups (Dataset S2). Together, these
results suggest that that S-BMO treatment acts primarily to re-
duce bone resorption.
Mechanistic Studies of Osteoclastogenesis. We next measured se-
rum levels of proteins known to regulate osteoclast differentia-
tion and function. Receptor activator of nuclear factor-kappa B
ligand (RANKL) induces osteoclast differentiation (25–27); it
was significantly decreased in colonized animals receiving S-BMO
(Fig. 3A). Osteoprotegerin opposes the activity of RANKL and
blocks signaling through its cognate receptor, RANK, to decrease
mature osteoclast formation (28, 29); Osteoprotegerin levels were
significantly greater in the S-BMO-treated group (Fig. 3B). The
decreased ratio of RANKL to osteoprotegerin suggested a shift
away from a pro-osteoclastogenic environment; this conclusion is
further supported by the observation that S-BMO-supplemented
animals had significantly reduced serum levels of osteopontin, a
mediator of osteoclast formation and function (30, 31) (Fig. 3C).
Myeloid lineage progenitors. Osteoclasts arise from myeloid cells,
and can be formed by fusion of monocytes, macrophages, and
their progenitors into multinucleated bone-resorbing cells (8)
(Fig. 3D). Using flow cytometry (SI Appendix, Supplementary
Materials and Methods), we identified alterations in myeloid
lineage commitment within the bone marrow of S-BMO-treated
mice; these include significant reductions in the representation
of Lin− IL-7Rα− cKit+ Sca1− CD34+ CD16/32+ granulocyte
monocyte progenitors and Lin− CD115+ cKit+ Flt3− Ly6C+
CD11b− common monocyte progenitors (32, 33) (Fig. 3 E and F
and Dataset S3A). Comparison of the two treatment groups also
revealed that mice receiving S-BMO had significantly higher
numbers of mature CD115+ cKit− Flt3− CD11b+ Ly6C+ bone
marrow monocytes (Fig. 3G and Dataset S3A), but no differ-
ences in the representation of other differentiated cell types in
the myeloid lineage (eosinophils and neutrophils; Fig. 3 H and I
and Dataset S3A). The effects of S-BMO supplementation were
specific to the myeloid lineage; there were no statistically sig-
nificant differences in the number of common lymphoid pro-
genitors or megakaryocyte-erythroid progenitors between the
two treatment groups (Dataset S3). Together, these findings
support the notion that S-BMO supplementation promotes
monocyte development at the expense of osteoclast formation.
Cytokines and chemokines linked to bone turnover. S-BMO did not
significantly affect serum levels of IL-4 or IL-13, two Th2 cyto-
kines known to negatively regulate osteoclast formation (Dataset
S2). IL-6, which promotes osteoclast formation and can con-
tribute to Th17-driven inflammation (34, 35), did not exhibit
significant differences in its serum levels between the two
treatment groups (Dataset S2). Transgenic mice that overexpress
IL-5, an important eosinophil growth factor, show ectopic bone
formation in their spleen (36). Although measurements of this
serum cytokine did not disclose significant differences between
the two groups of mice (Dataset S2), S-BMO produced a sig-
nificant increase in serum eotaxin-1 (Fig. 4A). Eotaxin-1/
CCL11 is chemotactic for Th2-associated eosinophils (37); its
expression is regulated by NF-κB and can be induced by proin-
flammatory cytokines including IL-4, IL-13, IL-1α, and TNFα
(38–40).
To further define the mechanism by which S-BMO decreases
osteoclast formation and bone resorption, we investigated shifts
in immune signaling and cellular composition within the in-
testine. Flow cytometry of colonic lamina propria cells (SI Ap-
pendix, Supplementary Materials and Methods) disclosed that mice
fed the S-BMO-supplemented diet had significantly elevated
levels of CD45+ CD11c− CD11b+ SiglecF+ eosinophils (Fig. 4B),
but not neutrophils or monocytes (Dataset S3). In keeping with
the increased eosinophils, eotaxin-1 levels in cecal tissue were
significantly higher in mice consuming S-BMO (Fig. 4C). IL-1α
and IL-10 promote and decrease osteoclast differentiation, re-
spectively, by influencing systemic levels of RANKL and osteo-
protegerin (41, 42). Animals receiving S-BMO had significantly
lower cecal tissue levels of proinflammatory IL-1α (Fig. 4D) and
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trended toward having higher tissue levels of IL-10 compared
with controls (P = 0.056; Fig. 4E).
T-cell responses are known to have important effects on os-
teoclast development; T regulatory cells can inhibit osteoclast
formation via production of IL-10 (43, 44), whereas immune
responses linked to the Th17 axis, including production of IL-
17A and IL-23, can enhance osteoclast differentiation (9). The
microbiota can, in turn, influence Th17 and T regulatory cell
expansion (45, 46). We found no statistically significant differ-
ences in overall T-cell number, or in the number of CD4+ T cells,
FoxP3+ T regulatory cells, or IL-17+ Th17 cells in the colons of
mice belonging to the two treatment groups (Dataset S3).
Intestinal gene expression. There is evidence from infants consuming
breast milk that a small fraction of sialylated oligosaccharides may
be absorbed in the small intestine (47). Therefore, we performed
RNA-Seq, using RNA isolated from the distal third of the small
intestines of mice in both treatment groups. An analysis of dif-
ferential gene expression (DESeq2; see SI Appendix, Supplementary
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Materials and Methods) identified 164 genes whose expression was
significantly altered by the addition of S-BMO to the base diet
(Fig. 4F and Dataset S4A). A comprehensive literature analysis
was performed to identify relevant biological processes and path-
ways represented by the differentially expressed genes; this was
accomplished with an automated Biological Knowledge Genera-
tion Engine that extracts all abstracts from PubMed that reference
genes of interest (or their synonyms), using natural language pro-
cessing and a biological language dictionary that is not restricted to
fixed pathway and ontology knowledge bases. Conditional proba-
bility analysis calculated the statistical enrichment of biological
concepts (processes/pathways) over those that occur by random
sampling. Related concepts built from the list of differentially
expressed genes were further clustered into higher-level themes
(e.g., biological pathways/processes; see SI Appendix, Supplemen-
tary Materials and Methods).
A number of genes in the eosinophil theme exhibited signifi-
cant differences in their expression in mice receiving S-BMO
(Dataset S4B); they include increases in expression of siglecF,
which encodes sialic acid binding Ig-like lectin F, a marker of gut
eosinophils; CD300lf, which specifies a glycoprotein that augments
IL-4- and IL-13-induced signaling, negatively regulates MyD88 and
TRIF-dependent TLR signaling, and inhibits osteoclast formation
(48–50); Hck, a regulator of innate immune responses that acts
downstream of multiple cytokine receptors (IL-2, IL-6, IL-8) (51);
andDefb1, a defensin reported to have a protective effect against the
development of inflammatory bowel disease in humans (52).
Moreover, Dusp5, a negative regulator of eosinophil survival and
function, was suppressed (53) (Fig. 4F).
Small intestinal tuft cells. Tuft cells are chemosensory members of
the gut epithelium derived from LGR5+ crypt stem cells; they
are distributed along the length of the gut and possess a dis-
tinctive cluster of microvilli at their apical surface. In addition,
volume-rendering ultrastructural studies have disclosed an
elaborate tubular network that includes cytospinules that con-
nect tuft cells to the nuclei of neighboring epithelial cells (54).
Their elaborate tubular connections to other epithelial cells, as
well as to the gut lumen, allows tuft cells to serve as sentinels;
one manifestation of this function is to orchestrate T-helper type
2 (Th2) immune responses to microbes (55, 56). A recent study
showed that succinate, a product of bacterial fermentation, signals
through the succinate receptor 1 (Sucnr1) and free fatty acid re-
ceptor 3 (Ffar3) on intestinal tuft cells to trigger a Th2 immune
response that includes increases in eosinophils (57). S-BMO-
treated mice had significantly higher levels of succinate in their
cecal contents compared with animals fed the unsupplemented
M8 diet (Fig. 4G and Dataset S5A). Moreover, expression of
Scnr1 and Ffar3 were both significantly increased in S-BMO-
treated mice (Fig. 4F), along with the small intestinal tuft cell
markers Gnat3 (guanine nucleotide binding protein G subunit
alpha 3), Trpm5 (transient receptor potential cation channel
subfamily M member 5), and Dclk1 (double cortin-like kinase 1)
(Dataset S4). On the basis of these observations, we used an an-
tibody to DCLK1 to stain sections obtained from the proximal,
middle, and distal thirds of the small intestine for tuft cells (n =
5 animals/treatment group). The results revealed significant S-
BMO-associated increases in the numbers of tuft cells along the
length of the small intestine (Fig. 4 H and I).
Overall, these results demonstrate that in colonized mice,
S-BMO supplementation of the diet produces (i) a reduction
in osteoclasts and their bone marrow myeloid progenitors, but
no demonstrable effect on osteoblasts, (ii) corresponding changes in
regulators of osteoclastogenesis [i.e., a reduction in an inducer of
osteoclast differentiation (RANKL) and an accompanying increase
in an inhibitor of this process (osteoprotegerin)], and (iii) changes in
chemokines, cytokines, and cells linked to Th2 responses [i.e., local
(intestinal) and systemic (serum) levels of eotaxin-1, increases in
colonic eosinophil number, plus tuft cell responses to succinate].
Comparing Germ-Free and Colonized Mice Fed S-BMO Versus 2′-FL. To
examine the role of the gut microbiota in mediating the effects of
S-BMO on bone biology, we compared groups of age-matched
male germ-free and colonized mice that had been killed after
monotonously consuming either the S-BMO-supplemented or
unsupplemented M8 diet for 42 d (n = 5 animals/treatment
group; Fig. 2A). We also characterized the specificity of the ef-
fects of S-BMO on bone biology. Rather than using LNT (lacto-
N-tetraose) or LNnT (lacto-N-neotetraose) as a nondecorated
HMO control that has N-acetylglucosamine, we added 2′-FL to
the drinking water of separate groups of colonized and germ-free
mice fed the base M8 diet (n = 5 mice/treatment group). This
HMO is a major component of breast milk in secretor mothers
who possess a functional FUT2 gene (58) and is currently being
added to some infant milk formulas.
Microbial community structure and metabolism. Supplementation with
2′-FL produced modest changes in cecal microbial community
composition, with only two bacterial taxa (Bifidobacterium
catenulatum and Collinsella aerofaciens) exhibiting significant
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Fig. 3. Effects of S-BMO on osteoclastogenesis. (A–C) Serum levels of
RANKL, osteoprotegerin (OPG), and osteopontin. (D–F) Bone marrow oste-
oclast progenitors enumerated via flow cytometry. Diagram of osteoclast
differentiation (D). Numbers of granulocyte-monocyte progenitors [GMP;
defined as Lineage (Lin)− IL-7Rα− cKit+ Sca1− CD34+ CD16/32+ cells; (E)] and
common monocyte progenitors [CMoP; Lin− CD115+ cKit+ Flt3− Ly6C+
CD11b− cells (F)]. See Methods for a list of Lineage markers. (G–I) Repre-
sentation of bone marrow monocytes [CD115+ cKit− Flt3− CD11b+ Ly6C+ cells
(G)], eosinophils [CD45+ CD11b+ CD11c− SiglecF+ cells (H)] and neutrophils
[CD45+ CD11b+ CD11c− Ly6G+ cells (I)]. Each dot in A–C and E–I indicates the
value for an individual animal with horizontal lines representing mean val-
ues. ns, not significant; *P < 0.05; **P < 0.01 (Mann–Whitney U test).
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differences in their relative abundances; the representation of these
organisms was not significantly affected by S-BMO (Dataset S1A).
Targeted gas chromatography (GC)-mass spectrometry of cecal
contents revealed that in this community context, the increase in
succinate levels was specific to S-BMO-treated animals and was
microbiota-dependent (Dataset S5).
The bacterial consortium introduced into mice contained a
total of 29 genes encoding known or predicted sialidases and
30 fucosidases. The distribution of these genes in members of the
defined community, and their assignments to different families
of carbohydrate active enzymes, are described in Dataset S1B.
Nontargeted liquid chromatography-quadrupole time-of-flight
mass spectrometry of cecal contents, harvested at the time of
euthanasia from colonized and germ-free mice fed the M8 diet
with or without S-BMO, revealed that the predominant product
of bacterial S-BMO metabolism was N-acetyl-2,3-dehydro-2-
deoxyneuraminic acid (SI Appendix, Fig. S1). This metabolite
was not detected in the serum of S-BMO-treated colonized mice,
nor in the ceca or serum of colonized mice fed the unsupple-
mented control diet or in germ-free mice fed either of the two
diets (SI Appendix, Fig. S1). The biological effects of this com-
pound are poorly defined, as are its interactions with Siglecs,
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including SiglecF or Siglec15 [the latter regulates osteoclast differ-
entiation through its modulation of RANKL signaling (59)].
Nonetheless, the absence of detectable serum levels of the metab-
olite suggests it is not involved in direct signaling from gut to bone.
Immune and bone phenotypes. In contrast to its effects in colonized
mice, S-BMO administration to germ-free animals did not pro-
duce statistically significant effects on body weight (17.23 ±
0.95 g vs. 19.1 ± 0.27 g for controls; P = 0.99, Mann–Whitney U
test) or alter femoral cortical bone thickness (0.11 ± 0.004 mm
vs. 0.11± 0.003 mm for controls; P = 0.15, Mann–Whitney U
test), or significantly affect serum levels of RANKL, IL-1ɑ, or
IL-10 (Dataset S2), nor did it decrease bone marrow granulocyte
monocyte progenitors or affect the representation of bone
marrow common monocyte progenitors and mature monocytes
(Dataset S3). Unlike colonized mice fed S-BMO, colonic eo-
sinophils were reduced rather than increased in germ-free mice
(0.98 ± 0.24% vs. 3.28 ± 0.59% of live cells; P < 0.05, Mann–
Whitney U test). However, S-BMO supplementation of the
M8 diet was sufficient to increase trabecular volume in germ-free
animals (8.57 ± 0.45% of total bone volume vs. 5.83 ± 0.41% for
controls; P < 0.05, Mann–Whitney U test), increase serum
osteoprotegerin, and decrease serum CTX-I (Dataset S2), sug-
gesting that S-BMO can influence bone resorption, but requires
the microbiota to exert its full effect on osteoclast lineage com-
mitment and immune signaling. As there are small differences in
micronutrient content between the two diets, including calcium
and phosphorus which are higher in S-BMO-supplemented M8
(388 vs. 428 ppm and 1,143 vs. 1,291 ppm, respectively), we cannot
exclude the possibility that these and/or other constituents of S-
BMO contribute to the observed microbiota-independent effects.
In contrast to S-BMO supplementation, we did not observe sta-
tistically significant effects of 2′-FL supplementation on weight gain,
femoral trabecular volume, cortical thickness, the number of bone
marrow granulocyte monocyte progenitors, serum levels of CTX-I,
and eotaxin-1 or cecal succinate levels in colonized mice (SI Ap-
pendix, Fig. S2 A–F and Dataset S5). However, unlike S-BMO,
common monocyte progenitors and mature monocytes were sig-
nificantly increased with 2′-FL administration (SI Appendix, Fig. S2
G and H), whereas colonic eosinophils were significantly decreased
(SI Appendix, Fig. S2I). As with S-BMO, 2′-FL did not have sig-
nificant effects on P1NP levels in colonized animals (Dataset S6).
Together, our results provide evidence of the specificity of S-
BMO’s effects on osteoclasts and their bone marrow progenitors,
regulators of osteoclastogenesis, and chemokines and cytokines
linked to Th2 responses. Moreover, they demonstrate that the
bacterial community obtained from the stunted infant was required
for the observed effects of S-BMO on cecal succinate levels, the
decrease in RANKL, the concomitant decrease in osteoclast pro-
genitors, and the colonic IL-1α, IL-10, and eosinophil responses.
Discussion
Our study has focused on the question of how interactions
among milk glycans, the gut microbiota, and the immune system
regulate bone growth. A corollary to this question is the degree
to which persistent stunting in children with undernutrition re-
flects increased osteoclastic activity and/or diminished osteo-
blastic activity. Although the GH/IGF1 axis is central to linear
growth via its actions on chondrocytes at the growth plate (60),
there is a relative paucity of studies that have examined the as-
sociation between biomarkers of bone turnover and growth fal-
tering in early childhood. One report disclosed a marked
increase in serum osteoprotegerin/RANKL ratios in neonates
who were born short for gestational age compared with those
with normal anthropometry, suggesting a potential compensatory
response, mediated by elevated osteoprotegerin, to delayed
neonatal growth (61). Furthermore, a systematic review and
meta-analysis of the effects of breastfeeding promotion inter-
ventions failed to find significant changes in ponderal or linear
growth (62), whereas a large prospective study in the Netherlands
documented an association between breastfeeding and higher bone
mass at 6 y of age (63). However, as breastmilk composition (in-
cluding its oligosaccharides) varies between mothers, as well as over
time within a given mother, the relationships between specific
molecular components of breast milk and physiologic outcomes/
biomarkers (such as linear growth/markers of bone turnover) are
difficult to define in the absence of carefully designed and well-
controlled longitudinal studies.
Previous preclinical studies of adult germ-free and conven-
tionally raised mice have linked the microbiota to regulation of
bone mass, although the effects reported are context-dependent,
with sex and genetic background influencing observed pheno-
types (e.g., refs. 64–66). Data about the effects of the microbiota
on bone biology in younger animals are more limited. Studies of
young, conventionally raised animals have shown that repeated
courses of treatment with orally administered antibiotics during
the first 40 postnatal days increase the rate of body mass gain and
bone growth (67). Lactobacillus rhamnosus promoted bone building
when introduced into young germ-free mice; the effect was associ-
ated with butyrate-induced increases in T regulatory cells (44).
Young germ-free mice fed a nutritionally depleted diet, but not their
conventionally raised counterparts, exhibited a growth hormone-
resistant state manifest in part by reduced femoral length and body
mass gain; the beneficial effect of a gut microbiota on the GH–IGF
axis was recapitulated in undernourished germ-free mice by mono-
colonization with Lactobacillus plantarum (68), prompting the au-
thors to emphasize the importance of advancing from these types of
preclinical observations to an analysis of the role of the gut micro-
biota on bone growth/stunting children with undernutrition (69).
In this report, we describe a cohort of stunted Bangladeshi
children with SAM who were studied before, during, and after
completion of nutritional rehabilitation with therapeutic foods.
The results reveal a significant reduction in plasma levels of a
biomarker of osteoclastic activity (CTX-1) by the end of treatment.
Although this reduction was sustained during the 6-mo period of
follow-up, it was not accompanied by changes in osteoblastic ac-
tivity, as assessed by plasma PN1P levels, nor was it associated with
any improvement in their severe stunting, suggesting that this re-
duction in osteoclast number/activity is insufficient to ameliorate
stunting without concomitant augmentation in osteoblastic function
and/or other anabolic processes.
In follow-up mechanistic studies conducted in gnotobiotic
mice, we provide evidence for a causal link between milk oli-
gosaccharides and regulation of osteoclast formation and func-
tion. When administered to gnotobiotic mice colonized with a
consortium of cultured bacterial strains from a 6-mo-old stunted
infant, this purified preparation of sialylated oligosaccharides,
recovered from normally discarded ingredients during the iso-
lation of whey protein, produced a reduction in osteoclasts and
their bone marrow myeloid progenitors without demonstrable
effects on osteoblasts. Mechanistic studies disclosed changes in
regulators of osteoclastogenesis, including a reduction in an in-
ducer of osteoclast differentiation (RANKL), an increase in an
inhibitor of this process (osteoprotegerin), plus alterations in
chemokines, cytokines, and cells linked to Th2 responses. The
interaction among S-BMO, the microbiota, and host distal small
intestinal, cecal, and colonic cell populations was manifested by
(i) decreased cecal tissue levels of a known promoter and in-
creased levels of a known inhibitor of osteoclast differentiation
(IL-1α and IL-10, respectively, which act through their effects on
systemic levels of RANKL and osteoprotegerin), (ii) increases in
cecal tissue levels of eotaxin-1 (chemotactic for Th2-associated
eosinophils), (iii) increases in expression of the gene encoding a
sialic acid binding Ig-like lectin F (SiglecF; a marker of gut eo-
sinophils) and suppression of Dusp5 (a negative regulator of
eosinophil survival and function), (iv) S-BMO and microbiota-
dependent increases in cecal levels of succinate, a product of
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microbial fermentation, and (v) increased numbers of small in-
testinal tuft cells with accompanying changes in expression of tuft
cell-associated genes indicative of activation of a signaling path-
way that involves the succinate receptor 1 (Scnr1) and triggers a
type 2 immune response leading to increases in the number of
eosinophils. Evidence for the specificity for these effects comes
from our finding that mice whose diets were supplemented with
2′-FL, a prominent fucosylated breast milk oligosaccharide, did
not exhibit increases in trabecular bone volume, cortical thickness,
the number of bone marrow osteoclast progenitors, changes in
serum levels of CTX-I, or increases in eotaxin-1 and colonic
eosinophils.
These observations raise a number of questions that need to
be addressed in the future. The extent to which intestinal eo-
sinophils and tuft cells contribute to S-BMO-associated reduc-
tions in osteoclast formation, number, and activity documented
in this preclinical model remains to be deciphered. For example,
what are the relative contributions of these cell lineages to the
observed changes in effectors that regulate osteoclastogenesis?
To what degree do tuft cell-based Th2 responses drive the gut
eosinophil response? What are the cellular origins of the S-
BMO-associated increase in eotaxin-1 in the gut and in periph-
eral blood? The lack of detectable protein in the S-BMO
preparation suggests that the eosinophilia we document in the gut is
not obviously related to the presence of this type of milk allergen
(70). Although the S-BMO preparation is predominantly com-
posed of sialyllactose, it contains other glycan components that
could potentially contribute to the observed effects on the im-
mune system and osteoclastogenesis. New synthetic approaches
are now enabling production of other purified milk oligosac-
charides at scale.
Our results with S-BMO and 2′-FL emphasize the need to test,
in preclinical models, the effects of other purified oligosaccha-
ride structures, singly at different doses and in different combi-
nations, on bone growth as well as other facets of host
physiology; the results should provide a more comprehensive
understanding of the biological functions of human breast milk
glycans and facilitate design of more effective therapeutic in-
terventions for infants at risk for, or with already evident un-
dernutrition (71). Advances in mass spectrometry have enabled
the development of methods for rapid, absolute quantification of
the numerous oligosaccharide structures present in breast milk
(72). Our findings also provide a rationale for initiating studies of
mothers and their offspring enrolled in birth cohorts in which
consent/ethical approval has been obtained for serial collection of
anthropometric data, breast milk, fecal samples, and plasma.
Correlating results obtained from analyses of oligosaccharide
structures present in breast milk, the biotransformation of these
structures by the gut microbiota, microbiota development, and
plasma biomarkers of bone development should provide new insights
about interactions among HMOs, microbiota assembly/maturation,
immune function, osteoclast and osteoblast development/activities,
and linear growth.
Materials and Methods
Methods and protocols used for the study of children with SAM, colonization
of gnotobiotic mice with a defined consortium of sequenced bacterial strains
cultured from a stunted infant, quantification of the effects of S-BMO and 2′-
FL on microbial community structure by short read shotgun sequencing of
cecal DNA, GC-mass spectrometry and liquid chromatography-quadrupole
time-of-flight mass spectrometry of metabolites present in cecal contents
and serum, microcomputed tomography of bone, histochemical and dy-
namic histomorphometric analyses of bone, flow cytometry of bone marrow
and cecal cell populations, RNA-Seq of distal small intestinal gene expres-
sion, histochemical and immunohistochemical analysis of intestinal sections,
and measurement of cytokines, chemokines, and mediators of bone devel-
opment and other proteins in serum and cecal tissue are described in SI
Appendix, Supplemental Materials and Methods. The study of children with
SAM was approved by the Ethical Review Committee at the International
Centre for Diarrhoeal Disease Research, Bangladesh, and written informed
consent was obtained from the parents or guardians of the study partici-
pants. Coded specimens and metadata were provided to Washington Uni-
versity under a materials transfer agreement (MTA) with approval from the
Washington University institutional review board. Samples were stored at
−80 °C in a dedicated biospecimen repository before analysis.
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